TradingView report covering Agape ATP Corporation (ATPC) market action, institutional positioning, and fundamental catalysts.
Why ATPC Stock dropped -10.22% Today — RQD Quant Desk Flash
Agape ATP Corporation (ATPC) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ATPC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Agape ATP Corporation (NASDAQ: ATPC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.45 (-10.22% 1D, market cap $1.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ATPC ranks #569 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ATPC compare to CCM and DCGO in the Health Care sector?
▼
Within the Health Care sector (Medical/Nursing Services), ATPC carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 55.0%, and ROIC of -11.5%. By comparison, CCM (Concord Medical Services Holdings Limited (Each represents thirty (30) ) (Class A)) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $15.9M) and DCGO (DocGo Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $27.0M). Among the 5-stock peer group, ATPC leads on earnings multiple (N/A) while ATPC leads on capital efficiency (-11.5% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ATPC?
▼
Per ATPC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001713210), Agape ATP Corporation generated $1.5M in revenue (+15.2% YoY), -$2.3M in net income, and -$2.4M in free cash flow against $24.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 33.2 (NEUTRAL RANGE)
Capital intensity & 0% operating margin leave 16 pts on the table
⚔️ Adversarial Opposing Case: What Could Spark a ATPC Turnaround Squeeze
While ATPC currently carries a cautious 39/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.07) and Max Pain ($1.52) forces dealer call-delta covering toward $77.17.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why ATPC Stock dropped -10.22% Today — RQD Quant Desk Flash
Agape ATP Corporation (ATPC) dropped -10.22% to $1.45, trading at 2% of its 52-week range ($1.31 – $73.5). Stretched risk/reward at current multiples (-12% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.31 – $73.5) with RSI-14 at 33.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.45 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 55% gross margin and $0 annual free cash flow.
Yahoo Finance UK report covering Agape ATP Corporation (ATPC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Agape ATP Corporation (ATPC) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Agape ATP Corporation (ATPC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Agape ATP Corporation (ATPC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Agape ATP Corporation (ATPC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Singapore report covering Agape ATP Corporation (ATPC) market action, institutional positioning, and fundamental catalysts.
Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings (NASDAQ:ITOC) shares
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ATPC)
- ✓Walkthrough of ATPC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
ATPC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +15.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ATPC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ATPC. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ATPC)
1. Head-to-Head Health Care Peer Comparison (ATPC vs. CCM, DCGO, PIII, BMGL)
Industry: Medical/Nursing Services (29 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Agape ATP Corporation (ATPC) ranks #569 by composite RQD confidence (39/100, grade D-) and #1008 by equity capitalization ($1.6M). Within this direct 5-issuer industry benchmark cohort, ATPC leads on earnings valuation at N/A trailing P/E, while ATPC leads on capital efficiency and profitability with -11.5% ROIC and 55.0% gross margin. BMGL currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with ATPC at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ATPC
ACTIVE
Agape ATP Corporation | D- | 39/100 | — | 55.0% | -11.5% | -10.22% | $1.6M | Benchmark Subject |
| CCM Concord Medical Services Holdings Limited (Each represents thirty (30) ) (Class A) | E | 22/100 | — | 5.7% | -35.0% | -2.46% | $15.9M | /ccm-vs-atpc → |
| DCGO DocGo Inc. | D- | 41/100 | — | — | -35.0% | -9.59% | $27.0M | /dcgo-vs-atpc → |
| PIII P3 Health Partners Inc. (Class A) | E | 24/100 | — | — | -35.0% | -4.05% | $30.5M | /piii-vs-atpc → |
| BMGL Basel Medical Group Ltd | D+ | 53/100 | — | — | — | +6.11% | $36.0M | /bmgl-vs-atpc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001713210In its most recent audited fiscal period (FY2025, filed 2025-12-31), Agape ATP Corporation (ATPC) reported GAAP revenue of $1.5M (+15.2% vs. FY2024 revenue of $1.3M , and +6.5% cumulative change since FY2023) , GAAP net income of -$2.3M, operating cash flow of -$2.4M, and free cash flow of -$2.4M (+11.5% YoY). On the balance sheet, ATPC closed FY2025 with $24.6M in total assets against $0 in total debt (Altman Z-Score: 0.49, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.5M | -$2.3M | -$2.4M | -$2.4M | $24.6M | — |
| FY2024 (FY) | 2024-12-31 | $1.3M | -$2.5M | -$2.7M | -$2.7M | $3.2M | — |
| FY2023 (FY) | 2023-12-31 | $1.4M | -$2.1M | -$2.0M | -$2.0M | — | — |
3. ATPC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ATPC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Agape ATP Corporation (NASDAQ: ATPC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.45 (-10.22% 1D, market cap $1.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ATPC ranks #569 in composite RQD confidence.
How does ATPC compare to CCM and DCGO in the Health Care sector?
Within the Health Care sector (Medical/Nursing Services), ATPC carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 55.0%, and ROIC of -11.5%. By comparison, CCM (Concord Medical Services Holdings Limited (Each represents thirty (30) ) (Class A)) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $15.9M) and DCGO (DocGo Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $27.0M). Among the 5-stock peer group, ATPC leads on earnings multiple (N/A) while ATPC leads on capital efficiency (-11.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ATPC?
Per ATPC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001713210), Agape ATP Corporation generated $1.5M in revenue (+15.2% YoY), -$2.3M in net income, and -$2.4M in free cash flow against $24.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ATPC trading relative to its 50-day, 200-day, and 52-week technical levels?
ATPC last traded at $1.45 (-10.22% on volume of 16,025 shares), positioning the stock -29.95% below its 50-day simple moving average ($2.07) and -45.49% below its 200-day simple moving average ($2.66). Across its 52-week range of $1.31 to $73.50, ATPC sits at the 0.2% percentile with a 14-day RSI of 33.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.27 to $1.63).
ATPC Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ATPC stock moving today?
Why ATPC Stock dropped -10.22% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-12% return on capital) under elevated 10-year interest-rate pressure.
ATPC — Agape ATP Corporation: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ATPC scores 39 out of 100, grade D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
- Fundamental Cash Engine (4 / 20): Per the Roarable RQD rating, ROIC is -11.5% and FCF yield is 0%. The company is not currently generating returns on capital or free cash flow to offset its losses. For a prospective investor, this removes the cash-flow floor that often supports valuation in micro-cap names.
- Whale 13F Flow (11 / 20): Per the Roarable RQD rating, institutional accumulation and options positioning are scored at a moderate level. The pillar summary does not provide holder-level detail, so the direction of institutional flow cannot be confirmed from the data here.
- Insider Conviction (5 / 20): Per the Roarable RQD rating, SEC Form 4 and Congressional PTR cluster flow are weak. Limited insider conviction means management is not signaling confidence through open-market activity, per the rating.
- Macro Regime Fit (11 / 20): Per the Roarable RQD rating, beta is 1.0 with moderate sector sensitivity. The stock is not defensively positioned against broad market moves, and its recent price action (-10.49% on the day) reflects that exposure.
- Forensic Balance Sheet (8 / 20): Per the Roarable RQD rating, Altman Z is 0.49, Piotroski F is 4/9, and Debt/Equity is 0.5. The Altman Z reading sits in a distress-range territory, which is the core reason this pillar is weak.
Investor implications: The upside case rests on a turnaround in operating margins from -60% toward breakeven, which the data does not show as underway. The valuation tradeoff is that with no positive earnings (P/E not available in source data) and a market cap of $1.6M against a 52-week range of $1.31 - $73.5, the stock has already experienced severe price compression. The second-order risk is financing: with cash at $0.1M in FY 2025 and FCF of $-2.4M, the company's ability to fund operations without dilution or new capital is a central open question.
Business
Agape ATP Corporation (ATPC) is a NASDAQ-listed issuer in the Health Care sector, Medical/Nursing Services industry. Per the company profile, its market capitalization is $0.0B. Per the SEC financials, the company reported revenue of $1.5M for FY 2025, with gross margin of 55% per the market data. The source data does not describe the specific products or services sold, its customer base, or its monetization model beyond these figures.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $1.5M | $-3.3M | $-2.3M | N/A | $-2.4M | $0.1M | N/A |
| FY 2024 | $1.3M | $-2.6M | $-2.5M | N/A | $-2.7M | $2.0M | N/A |
| FY 2023 | $1.4M | $-2.1M | $-2.1M | N/A | $-2.0M | N/A | N/A |
Per the SEC financials, the company has reported operating losses in each period shown, with operating margin at -60% and net margin at -60% per the market data. Per the Roarable RQD rating, ROIC is -11.5%. Altman Z is 0.49 and Piotroski F is 4/9 per the forensic balance sheet pillar. Cash declined from $2.0M in FY 2024 to $0.1M in FY 2025, and FCF has been negative across all three reported periods.
Recent Catalysts & News Wire Analysis
The news feed contains six items, all referencing ATPC, with no specific operational catalyst described in the summaries. Items are generic aggregator or market-wire entries (TradingView, Yahoo Finance UK, Yahoo! Finance Canada) and one reference to an earnings report.
- Market Wire (YELLOW): Multiple items labeled MARKET WIRE carry a YELLOW light, indicating neutral-to-cautionary attention but no specific event.
- Risk Watch (RED): One item, an earnings-related headline titled "ATPC Q4 2024 Earnings: Reported Loss of $0.20 per Share as Stock Slips 6.36%," is flagged RISK WATCH with a RED light. Its summary text is not a meaningful description of the company and appears to be a misattributed source reference, so the earnings figure should be verified against primary filings.
- The Butterfly Supply-Chain Graph shows no supply-chain links and no proprietary signals.
Open Questions
- What is the company's specific product or service mix, and what drives its $1.5M revenue base?
- How does the company intend to fund operations given $0.1M cash and $-2.4M FCF in FY 2025?
- What explains the 52-week range of $1.31 - $73.5, and is there a recent corporate event behind it?
- Does the Q4 2024 earnings headline (loss of $0.20 per share) reconcile with the reported financials, and what is the correct EPS?
- What is the debt position, since the source data reports debt as N/A for every period?
ATPC Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Agape ATP Corporation (ATPC) • Click "Debate This Headline" to argue it in the Roar Pit below
TradingView report covering Agape ATP Corporation (ATPC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Agape ATP Corporation (ATPC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Agape ATP Corporation (ATPC) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Agape ATP Corporation (ATPC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Agape ATP Corporation (ATPC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Agape ATP Corporation (ATPC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Singapore report covering Agape ATP Corporation (ATPC) market action, institutional positioning, and fundamental catalysts.
Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings (NASDAQ:ITOC) shares
ATPC Bull vs. Bear Conversation Board — What's Your Call at $1.45?
🔥 Official Bull vs. Bear Debate: Is ATPC (D- • RQD 39/100) a Buy at $1.45?
Welcome to the ATPC (Agape ATP Corporation) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical/Nursing Services. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on ATPC — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ATPC, but look at what you are paying: current EV/EBITDA multiples with 55.0% gross margins. Unless Agape ATP Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
ATPC cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ATPC, the market is fixating on short-term headline noise in Medical/Nursing Services and ignoring the balance sheet and cash flow trajectory. At $1.45 (52-wk range $1.31 - $73.50), any beat on forward guidance forces shorts and underweight funds to chase.